Swiss CRO Atheris Laboratories has signed a deal with Debiopharm to help develop a peptide cancer drug, optimizing leads through its innovative venom-derived platform. Under the agreement, Atheris ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback